Neena Gupta redefines timely care with Cipladine
Cipla Health
, a player in
consumer healthcare
, has announced the launch of its latest campaign, "
Cipladine
– Aapka
Fast Aid Expert
," featuring actress
Neena Gupta
as the brand ambassador.
The campaign reinforces Cipladine's positioning as India's No.1 trusted solution for cuts, wounds, burns and infections — delivering fast and effective healing when it matters most.
Backed by its
Povidone Iodine
(PVPI) formula, Cipladine is proven to stay longer on the skin, penetrate deeper, and start acting within just 30 seconds, making it not just a first aid but true Fast Aid Expert.
Shivam Puri, managing director and chief executive officer, Cipla Health said, 'With our new 'Fast Aid' campaign, we're redefining timely care, delivering quick, effective relief when it's needed most. This latest narrative reaffirms Cipladine's place as a household essential, trusted across both urban and rural India. We're delighted to have Neena Gupta bring her authenticity and wide appeal to help take this message forward."
Conceptulised by
Lowe Lintas
, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films featuring Neena Gupta and Shashie Verma.
In these quirky and relatable stories, Gupta, a meticulous and quick-witted character, is often seen outpacing her slow, laid-back assistant, echoing Cipladine's rapid action on wounds.
Gupta, actress and brand ambassador, shared her excitement about the association, saying, 'Cipladine is quick, reliable, and versatile, it reminds me of the kind of roles I enjoy doing. Being a part of this campaign was a delightful experience.'
Subramanyeswar S, group chief executive officer- India and chief strategy officer – APAC, MullenLowe Global said, 'We asked ourselves: how can a leader lead even more distinctively? The answer emerged in a powerful insight - speed - a critical need in first aid. That's when we reimagined Cipladine not just as a product, but as a solution—a fast aid expert in the world of
first aid solutions
.'
Sarvesh Raikar, president (creative), Lowe Lintas added, 'The idea of an ultra-efficient boss and her quest to set things right without wasting time served as a perfect backdrop to launch our refreshed brand idea – to move from 'first aid' to 'fast aid' expert. The chronicles of Neena Gupta and her secretary Sashi Verma, directed by Vivek Dubey, effortlessly bring alive our new narrative of speed, while also bringing a smile on the viewers faces.'
The campaign is now live across TV, digital, print, OOH and trade visibility assets, to ensure maximum reach and engagement.
Watch the videos here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Wire
2 days ago
- The Wire
Antibiotics, Diabetes and BP Drugs, Vitamin Supplements Found to Be Not of Standard Quality in June
Health Banjot Kaur Issues that Union and state regulators detected during their monthly inspections include contamination and incorrect labelling. Representative image of tablet drugs. Photo: New Delhi: Batches of as many as 185 drugs were found to be not of standard quality (NSQ) by Union and state drug regulators during their monthly inspection in June. The results of their inspections were released on Friday (July 18). A drug is labelled NSQ if it does not meet the quality standards laid down in the Indian laws governing drugs. The Central Drugs Standard Control Organisation (CDSCO) found batches of 55 drugs NSQ, with batches of the remaining 130 being flagged by various state drug regulators. The CDSCO is India's drug regulator at the Union government level. This is not a one-off list. It is a monthly document that the CDSCO publishes. The exercise became regular about a year ago. 'As part of the continuous regulatory surveillance, drug samples are picked from sales/distribution point and analysed, and the list of spurious [NSQ] drugs are displayed on the CDSCO portal on a monthly basis,' the CDSCO said. The purpose of displaying the list is to make stakeholders aware about the NSQ batches identified in the market, it added. The drugs that the CDSCO and state regulators most commonly found to be NSQ were mainly antibiotics, vitamin and calcium supplements, and anti-hypertensives (used for controlling blood pressure) in oral and injectable forms. The companies mentioned in this article are not the only ones whose products were found to be NSQ. We have only considered companies that made either multiple batches of a given drug that were found sub-par, or those that have manufactured various drugs that were found sub-par. It must be mentioned here that the CDSCO's and the states' labs only test a certain batch(es) of a particular medicine. If one batch of any drug has been red-flagged, it does not necessarily mean that all its batches would be substandard. Common 'errors' One of the most serious risks associated with NSQ drugs is improper sterility. This means that the drug contains harmful microorganisms that can lead to infection in a patient's body after ingestion. This could potentially cause extremely serious complications in patients, like sepsis or even death due to acute infection. The other common problem that some drugs have is that they contain 'particulate matter' – particles that inadvertently enter the drug during the manufacturing process. These particles can contaminate the drug. A 'description' error is one in which a drug's physical appearance does not match its prescribed appearance as per regulation. For example, if a tablet is described in regulation as having a white colour but a patient finds it to be orange, the tablet would have a description error. Several medicines were reported as experiencing 'loss on drying'. This error reflects the lack of moisture in drugs, which may cause microbial growth in them, potentially causing infection if ingested. A drug is labelled as having assay errors when an ingredient in it is found in a quantity that is higher or lower than what is mentioned on its label. A higher amount would mean an overdose and a lower amount would result in an underdose – the latter would lead to a situation where a patient even after consuming the prescribed strength of a drug ends up ingesting a lower quantity of some ingredient. This can lead to their disease getting worse. 'Extractable volume' errors usually occur with vials. If the liquid that is to be extracted from a vial using a syringe is present in a quantity greater or lower than as labelled, this can again lead to an overdose or underdose of the drug given in injectable form. 'Dissolution' errors can adversely affect the absorption of a drug. What did the CDSCO find? Six drugs manufactured by Paksons Pharmaceuticals Private Limited were found to be NSQ. These include a dexamethasone sodium phosphate injection – an antibiotic; an ascorbic acid injection, used as a vitamin C supplement; an adrenaline bitartrate injection, used during cardiac arrest; an ondansetron injection, used for treating nausea caused by cancer medicines; and a gentamicin injection, used for treating bacterial injections. The company's diclofenac sodium injection, used as a pain killer, had extractable volume issues in its vials. Four batches of Phaex Polymers Private Limited's colestyramine (used to treat high cholesterol) and three batches of its sodium polystyrene sulfonate (for regulating potassium levels) reported 'loss of drying' mistakes. Zee Laboratories' tranexamic acid injection, used for controlling excessive loss of blood during surgery in patients suffering from hemophilia, reported assay problems. On the other hand, its glipizide & metformin tablets, used for treating high blood sugar, had a description error. Two batches of Overseas Health Care Pvt Ltd's calcium aspartate, calcium orotate, calcitriol minerals and vitamin tablets, which are used to supplement calcium and micronutrients like zinc and vitamins to treat deficiencies, had compromised assays for almost all of their ingredients. Martin & Brown BioSciences Pvt Ltd's calcium gluconate injection had particulate matter and description errors along with extractable volume issues. Three batches of its rabeprazole sodium injection – used to treat acid reflux – also had particulate matter and assay problems. Two batches of E.G. Pharmaceuticals' vitamin C injection and vitamin B12, folic acid and niacinamide injection had particulate matter and description errors. Two batches of Healers Lab's telmisartan tablets (used to manage blood pressure) had dissolution issues. What did state drug regulators find? State drug regulators too found serious errors in some drugs. Five batches of Puniska Injectables's sodium chloride injection had serious sterility problems. These injections have multiple purposes. They are primarily given in cases of dehydration to restore electrolytes (sodium and chlorine). Similarly, Paschim Banga's dextrose injection, which is used to normalise blood sugar levels, and its sodium chloride injection, had sterility issues. Thirteen batches of Martin & Brown BioSciences' calcium and vitamin D3 tablets had description errors. Vivek Pharmachem's paracetamol and ciprofloxacin hydrochloride tablets had description and dissolution issues respectively. Safe Care Life Sciences's mecobalamin 2,500 mg injection, which is used for vitamin B12 supplementation, had 2.38 mg per ml of mecobalamin against the labelled claim of 2,500 mg per ml in its vial. Two batches of Oscar Remedies's ciprofloxacin & dexamethasone eye/ear drops had 943.33% more ciprofloxacin than the labelled amount. The full lists of NSQ drugs made by the CDSCO and state regulators can be found here and here respectively. The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.
Time of India
4 days ago
- Time of India
CORONA Remedies acquires 7 brands from Bayer's pharma division in India
CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum. The acquisition includes brands in the cardiology segment (Noklot) and women's healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market , the company said in a statement. Explore courses from Top Institutes in Select a Course Category Public Policy Artificial Intelligence Product Management Digital Marketing Cybersecurity Technology MBA CXO Healthcare Others Data Science Leadership PGDM Design Thinking healthcare Operations Management Data Analytics Data Science Project Management others Management MCA Finance Degree Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.
Time of India
4 days ago
- Time of India
TOI Impact: RUHS releases merit list for 1,700 med officer posts
Jaipur: The Rajasthan University of Health Sciences (RUHS) Tuesday released the merit list for appointment of 1,700 medical officers, days after TOI highlighted the inordinate delay in the declaration of results nearly three months after the exam. The recruitment process had been stalled since April 27, when the written exam was conducted. The release of the merit list now clears the way for filling long-pending vacancies for medical officers across the state. Medical officers play a crucial role in strengthening primary healthcare delivery. Many Primary Health Centres (PHCs) and Community Health Centres (CHCs) in Rajasthan currently function without doctors, affecting rural healthcare. "With the merit list out, the process of allotting postings to selected doctors will begin soon," said a senior health department official. Candidates will have to submit their posting preferences online. Based on their rank in the merit list, postings will be allocated accordingly, the official added. RUHS had been tasked with conducting the recruitment exam and managing the selection process, including release of the category-wise merit list. Document verification of about 3,400 candidates who cleared the exam was completed to ensure they met eligibility norms. Officials said, verification included checking for valid registration with the Rajasthan Medical Council, a mandatory requirement to practice in the state, along with scrutiny of disability and other reservation-related certificates. Based on these verified documents, RUHS will now finalise and release the detailed category-wise merit list, paving the way for formal appointments.
